-
Capital, M&A & Industry Strategy4 days agoKura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy
Kura Oncology has spun out a biotech armed with $50 million in fresh funding to take forward a next-generation diabetes treatment.
-
Capital, M&A & Industry Strategy4 days ago
Eli Lilly’s pipeline in 2026: how the incretin boom is funding what comes next
Take a look at the Eli Lilly pipeline in 2026 as the incretin franchise grows and fuels the rest of the company's pipeline. The post Eli...
-
Capital, M&A & Industry Strategy5 days agoSteady stream of crossover rounds stock biotech’s IPO pipeline
Biotech crossover rounds could top $4.22 billion across about 28 rounds this year, PitchBook forecasts.
-
Capital, M&A & Industry Strategy5 days ago
Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
Solstice Oncology has secured $225 million in series A funds to advance a next-gen immunotherapy that the biotech hopes will turn “darkness to light” for cancer...
-
Capital, M&A & Industry Strategy5 days agoNRAS Mutations May Require Mutation-Guided Combination Therapies
Mutant NRAS has remained difficult to target in cancer. New findings suggest that its signaling partnership with wild-type HRAS may offer a targetable vulnerability, but effective...
-
Capital, M&A & Industry Strategy5 days ago
Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics
Schrödinger announced the launch of new immune disease-focused Tectora Therapeutics, which comes online with a $55 million series A financing round.
-
Capital, M&A & Industry Strategy5 days agoNovartis RNA drug falls short in rare muscle disease study
The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.
-
Capital, M&A & Industry Strategy5 days agoBrainChild Bio targets deadly pediatric brain cancer with $116M series A
BrainChild Bio’s lead asset BCB-276 is in pivotal development for diffuse intrinsic pontine glioma, a rare and fatal brain tumor that affects around 300 children in...
-
Capital, M&A & Industry Strategy5 days agoPharma body sees ‘green shoots’ in UK investment
The UK is starting to benefit from a "real partnership" between pharma and government, reversing years of diminishing investment, says the ABPI.
-
Capital, M&A & Industry Strategy5 days agoNovartis India acquires Pfizer brands for $132m
The purchase adds an established hypertension brand to Novartis’ cardiovascular range. Novartis India’s board cleared the deal, after which the company signed an asset purchase agreement...
Carbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms
Your Zip Code May Shape Your Breast Cancer Tumor’s Genetics and Your Survival Odds
Azithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
